Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.2.629

Down-Regulation of Mcl-1 by Small Interference RNA Induces Apoptosis and Sensitizes HL-60 Leukemia Cells to Etoposide  

Karami, Hadi (Immunology Research Center, Department of Medical Immunology, Faculty of Medicine, Tabriz University of Medical Sciences)
Baradaran, Behzad (Immunology Research Center, Department of Medical Immunology, Faculty of Medicine, Tabriz University of Medical Sciences)
Esfehani, Ali (Hematology and Oncology Research Center, Shahid Ghazi Hospital, Tabriz University of Medical Sciences)
Sakhinia, Masoud (Faculty of Medicine, University of Liverpool)
Sakhinia, Ebrahim (Tuberculosis and Lung Diseases Research Centre, Department of Medical Genetics, Faculty of Medicine, Tabriz Genetic Analysis Centre, Tabriz University of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.2, 2014 , pp. 629-635 More about this Journal
Abstract
Background: Acute myeloid leukemia (AML) is a fatal hematological malignancy which is resistant to a variety of chemotherapy drugs. Myeloid cell leukemia-1 (Mcl-1), a death-inhibiting protein that regulates apoptosis, has been shown to be overexpressed in numerous malignancies. In addition, it has been demonstrated that the expression level of the Mcl-1 gene increases at the time of leukemic relapse following chemotherapy. The aim of this study was to target Mcl-1 by small interference RNA (siRNA) and analyze its effects on survival and chemosensitivity of acute myeloid leukemia cell line HL-60. Materials and Methods: siRNA transfection was performed with a liposome approach. The expression levels of mRNA and protein were measured by real-time quantitative PCR and Western blot analysis, respectively. Trypan blue assays were performed to evaluate tumor cell growth after siRNA transfection. The cytotoxic effects of Mcl-1 siRNA (siMcl-1) and etoposide were determined using MTT assay on their own and in combination. Apoptosis was quantified using a DNA-histone ELISA assay. Results: Transfection with siMcl-1 significantly suppressed the expression of Mcl-1 mRNA and protein in a time-dependent manner, resulting in strong growth inhibition and spontaneous apoptosis. Surprisingly, pretreatment with siMcl-1 synergistically enhanced the cytotoxic effect of etoposide. Furthermore, Mcl-1 down-regulation significantly increased apoptosis sensitivity to etoposide. No significant biological effects were observed with negative control siRNA treatment. Conclusions: Our results suggest that specific suppression of Mcl-1 by siRNA can effectively induce apoptosis and overcome chemoresistance of leukemic cells. Therefore, siMcl-1 may be a potent adjuvant in leukemia chemotherapy.
Keywords
Mcl-1; apoptosis; siRNA; etoposide; leukemia; HL-60;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Yang M, Mattes J (2008). Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs. Pharmacol Ther, 117, 94-104.   DOI   ScienceOn
2 Yecies D, Carlson NE, Deng J, Letai A (2010). Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood, 115, 3304-13.   DOI   ScienceOn
3 Zhang S, Li G, Ma X, et al (2012). Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1. Cell Signal, 24, 1803-9.   DOI   ScienceOn
4 Reischl D, Zimmer A (2009). Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine, 5, 8-20.   DOI   ScienceOn
5 Robak T, WierzbowskaI A (2009). Current and emerging therapies for acute myeloid leukemia. Clin Ther, 31, 2349-70.   DOI   ScienceOn
6 Shan G (2010). RNA interference as a gene knockdown technique. Int J Biochem Cell Biol, 42, 1243-51.   DOI   ScienceOn
7 Skoda C, Erovic BM, Wachek V, et al (2008). Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck. Oncol Rep, 19, 1499-503.
8 Szer J (2012). The prevalent predicament of relapsed acute myeloid leukemia. Hematol Am Soc Hematol Educ Program, 2012, 43-8.
9 Thallinger C, Wolschek MF, Maierhofer H, et al (2004). Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. Clin Cancer Res, 10, 4185-91.   DOI   ScienceOn
10 Thallinger C, Woschek MF, Wacheck V, et al (2003). Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol, 120, 1081-6.   DOI   ScienceOn
11 Warr MR, Shore GC (2008). Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med, 8, 138-47.   DOI   ScienceOn
12 Xiao J, Yin S, Li Y, et al (2009). SKP2 siRNA inhibits the degradation of P27kip1 and down-regulates the expression of MRP in HL-60/A cells. Acta Biochim Biophys Sin, 41, 699-708.   DOI   ScienceOn
13 Kupsa T, Horacek JM, Jebavy L (2012). The role of cytokines in acute myeloid leukemia: a systematic review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 156, 291-301.
14 Kano R, Yano T, Nagamatsu K, et al (2009). Effectiveness of small interfering RNA (siRNA) against the Mcl-1 gene in a canine mammary gland tumor cell line. Res Vet Sci, 87, 64-6.   DOI   ScienceOn
15 Kaufmann SH, Karp JE, Svingen PA, et al (1998). Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood, 91, 991-1000.
16 Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW (1993). MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A, 90, 3516-20.   DOI   ScienceOn
17 Li G, Chang H, Zhai YP, Xu W (2013). Targeted silencing of inhibitors of apoptosis proteins with siRNAs: a potential anti-cancer strategy for hepatocellular carcinoma. Asian Pac J Cancer Prev, 14, 4943-52.   과학기술학회마을   DOI   ScienceOn
18 LivakI KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2-$^{\Delta\Delta}CT$ Method. Methods, 25, 402-8.   DOI   ScienceOn
19 Quinn BA, Dash R, Azab B, et al (2011). Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs, 20, 1397-411.   DOI   ScienceOn
20 Montecucco A, Biamonti G (2007). Cellular response to etoposide treatment. Cancer Lett, 252, 9-18.   DOI   ScienceOn
21 Ramachandran PV, Ignacimuthu S (2012). RNA interference as a plausible anticancer therapeutic tool. Asian Pac J Cancer Prev, 13, 2445-52.   과학기술학회마을   DOI   ScienceOn
22 David S, Pitard B, Benoit JP, Passirani C (2010). Non-viral nanosystems for systemic siRNA delivery. Pharmacol Res, 62, 100-14.   DOI   ScienceOn
23 Brunelle JK, Ryan J, Yecies D, Opferman JT, Letai A (2009). MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts. J Cell Biol, 187, 429-42.   DOI   ScienceOn
24 Chetoui N, Sylia K, Gagnon-Houde JV, et al (2008). Downregulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis. Mol Cancer Res, 6, 42-52.   DOI   ScienceOn
25 Chou TC, Talaly P (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul, 22, 27-55.   DOI   ScienceOn
26 Glaser SP, Lee EF, Trounson E, et al (2012). Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev, 26, 120-5.   DOI   ScienceOn
27 Han P, Luan Y, Lin Y, et al (2013). Small interfering RNA targeting Rac1 sensitizes colon cancer to dihydroartemisinininduced cell cycle arrest and inhibited cell migration by suppressing NFkappaB activity. Mol Cell Biochem, 379, 171-80.   DOI   ScienceOn
28 Kanasty RL, Whitehead KA, Vegas AJ, Anderson DG (2012). Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther, 20, 513-24.   DOI
29 High LM, Szymanska B, WilczynskaI-Kalak U, et al (2010). The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol, 77, 483-94.   DOI   ScienceOn
30 Hussain SR, Cheney CM, Johnson AJ, et al (2007). Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximabmediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res, 13, 2144-50.   DOI   ScienceOn
31 Akagi H, Higuchi H, Sumimoto H, et al (2013). Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapyassociated apoptosis in gastric cancer cells. Gastric Cancer, 16, 100-10.   DOI   ScienceOn
32 Boisvert-Adamo K, Longmate W, Abel EV, Aplin AE (2009). Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res, 7, 549-56.   DOI   ScienceOn
33 Martins LM, Mesner PW, Kottke TJ, et al (1997). Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood, 90, 4283-96.
34 Smits EL, Berneman ZN, Van Tendeloo VF (2009). Immunotherapy of acute myeloid leukemia: current approaches. Oncologist, 14, 240-52.   DOI   ScienceOn